2022 - Bringing the Clinical Trial to the Patient in Preclinical Alzheimer’s Disease

With the first demonstration that anti-amyloid therapies can slow amyloid accumulation and reduce clinical disease progression in symptomatic Alzheimer’s disease, there is increasing focus on the extent to which disease modifying therapies, applied very early in AD, may delay symptom onset itself.
With focus turning to clinical trials in the preclinical stage of Alzheimer’s disease, clinical trial design is faced with new challenges and new opportunities. The requirement for identifying abnormal Alzheimer’s disease biology in cognitively unimpaired adults is being made easier with the industrialization of blood-based biomarkers for amyloid and tau. In the same vein, engaging, screening, recruiting and even assessing clinical status in cognitively unimpaired adults is facilitated through use of remote clinical assessment.
Clinical trial teams now need testing solutions that are effective and equivalent when deployed outside of the clinical site. Utilizing remote testing allows participants to be assessed from the comfort of their home, typically reducing the number of site visits, and supporting faster and more diverse recruitment which allows studies to be extended to include samples from underrepresented populations.
Cogstate technologies have been used in remote contexts in clinical trials and research for decades. This experience provides the basis for their current application in Phase III registration of trials of disease-modifying therapies in preclinical Alzheimer’s disease.
This webinar will consider the types of remote cognitive assessments that can be applied in clinical trials, aspects of trial design to which they apply and the methodological issues that require consideration when cognitive assessments are conducted remotely. The featured speakers conclude with consideration for the potential opportunities afforded by use of remote cognitive assessment in preclinical Alzheimer’s disease.